EUVIMEDEUVIMED entdecken
Kohortenstudie

Phenotypic Age Acceleration Predicts Survival Outcomes in HR+/HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Cohort Study

Tuğba Önder, Öztürk Ateş

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2026.07.013 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Tuğba Önder und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences University, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. Electronic addres…. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronological age alone poorly reflects physiologic vulnerability in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). We therefore evaluated phenotypic age acceleration (PhenoAgeAccel), a biomarker of biological aging, as a predictor of survival outcomes. METHODS: This retrospective cohort included 560 patients with HR+/HER2-negative mBC treated with CDK4/6i plus endocrine therapy between 2017 and 2025. PhenoAge was calculated using clinical biomarkers obtained within 1 month prior to treatment initiation, and PhenoAgeAccel was defined as the residual of PhenoAge regressed on chronological age. Patients were categorized as PhenoAgeAccel ≤ 0 or > 0. RESULTS: PhenoAgeAccel was evaluable in 530 patients; 38.3% exhibited PhenoAgeAccel > 0. Median follow-up for the entire cohort was 42.2 months (95% confidence interval [CI], 39.0-45.5). Median progression-free survival (PFS) was 21.1 months (95% CI, 18.6-23.5) and median overall survival (OS) was 49.9 months (95% CI, 41.8-58.0). Patients with PhenoAgeAccel > 0 experienced significantly shorter PFS and OS compared with those without acceleration (median PFS 14.0 vs. 27.6 months, hazard ratio [HR] 1.53, 95% CI, 1.17-2.01; P = .002; median OS 28.9 vs. 68.0 months, HR 1.81, 95% CI, 1.26-2.60; P = .001). The adverse prognostic impact of PhenoAgeAccel was consistent across predefined clinical subgroups. Patients with accelerated biological aging also demonstrated lower objective response (ORR) and disease control rates (DCR) (objective response rate 25.6% vs. 33.9%, P = .043; DCR 72.4% vs. 89.0%, P < .001). CONCLUSIONS: PhenoAgeAccel is an independent prognostic marker associated with inferior survival and reduced treatment response, suggesting that biological age may be more informative than chronological age in HR+/HER2-negative mBC treated with CDK4/6 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 6Protein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAgingHumansFemaleRetrospective StudiesErb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Receptors, ProgesteroneMiddle AgedReceptors, EstrogenAgedPrognosisAdultBiomarkers, TumorPhenotypeAged, 80 and overProgression-Free SurvivalAge Factors

Stichwörter der Autor:innen

Breast cancerPhenoAgePhysiological agingPrognosisRisk stratification

Substanzen

Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Receptors, ProgesteroneProtein Kinase InhibitorsERBB2 protein, humanReceptors, EstrogenCDK6 protein, humanCDK4 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Health Sciences University, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. Electronic address: ondertugba111@gmail.com.
  • Department of Health Sciences University, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.

Zitieren

APA

Önder, T., & Ateş, Ö. (2026). Phenotypic Age Acceleration Predicts Survival Outcomes in HR+/HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Cohort Study. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.07.013

Vancouver

Önder T, Ateş Ö. Phenotypic Age Acceleration Predicts Survival Outcomes in HR+/HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Cohort Study. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.07.013

BibTeX
@article{nder2026,
  author = {Önder, Tuğba and Ateş, Öztürk},
  title = {Phenotypic Age Acceleration Predicts Survival Outcomes in HR+/HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Cohort Study},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2026.07.013}
}
Kostenlos starten →